Design and In-vitro Evaluation of fast Disintegrating Promethazine Theoclate Tablets
Promethazine theoclate, a first-generation H1 receptor blocker, is commonly prescribed for motion sickness and postoperative nausea. Its oral bioavailability is only about 25%, mainly because of poor solubility in water, which delays the onset of action. To overcome this limitation, orally disintegrating tablets (ODTs) of promethazine theoclate were developed.